Bacterial lipopolysaccharide and surface protein (LPS and surface proteins)

Bacterial lipopolysaccharide (LPS) and surface proteins are essential components of the bacterial cell envelope that maintain structural integrity and mediate interactions with the host environment. LPS, also known as endotoxin, is a complex glycolipid found in the outer membrane of Gram-negative bacteria, consisting of Lipid A, a core oligosaccharide, and an O-antigen (NIH, NBK554414). It serves as a primary barrier against chemical attacks and is a potent trigger for the host's innate immune system via Toll-like receptor 4 (TLR4). Surface proteins, including outer membrane proteins (OMPs) and adhesins, are involved in nutrient acquisition, waste export, and adherence to host tissues, making them critical for bacterial survival and pathogenesis (UniProt, KW-0448). In clinical settings, LPS is a major driver of sepsis and septic shock, where its systemic release leads to an overwhelming inflammatory response. Therapeutic targeting of these components includes the use of polymyxin antibiotics, which disrupt the outer membrane by binding to Lipid A, and the development of monoclonal antibodies aimed at neutralizing endotoxins or blocking surface protein functions. However, drug development is often complicated by the high toxicity of membrane-disrupting agents and the potential for severe inflammatory reactions during bacterial lysis.

Other names

EndotoxinLipoglycanOuter membrane proteinOMPBacterial cell wall componentLipid A

Drugs such as polymyxins bind to the Lipid A moiety of lipopolysaccharide (LPS), displacing calcium and magnesium ions that stabilize the outer membrane, which leads to membrane disruption and cell lysis (StatPearls, NBK554414). Other therapeutic approaches involve inhibiting the transport of LPS to the cell surface via proteins like LptD or using monoclonal antibodies to neutralize the endotoxic activity of LPS and opsonize surface proteins for immune clearance (PubMed, PMC6471493).